… cohort 1), the initial dose of capecitabine was reduced to 750 mg/m 2 twice per day (cohort
2); doses of oxaliplatin and erlotinib … though these studies with gefitinib and erlotinib have the …

… In the Phase I portion, patients were enrolled in 3-patient cohorts at erlotinib dose levels of
… Ongoing studies are testing the concurrent use of gefitinib or erlotinib and an mTOR inhibitor…

… No patient entered the study on erlotinib. Of the 8 patients with prior erlotinib or gefitinib …
cohorts 1 and 2 to compare the human PK profile of the milled apricoxib agent used in this …

… cohorts … study with erlotinib, reported median progression-free survival was 14 months 11,
and in a pooled analysis examining five studies of first-line treatment with erlotinib or gefitinib …

… Of the nine patients enrolled in the gefitinib cohort, grade 1 and grade 2 adverse events were
observed in two (22%) and one (11%) patients, respectively, on standard dose. No grade 3 …

… The results of the study show that afatinib therapy was superior to erlotinib and gefitinib as
first-… type used was an analytic observational retrospective cohort study. The subjects of the …

… Gefitinib and erlotinib, small molecules reversibly binding the ATP pocket in the EGFR …
need validation in future studies. Finally, because this was a single cohort study without a control …

… EGFR-TKIs such as erlotinib and gefitinib are highly effective for the treatment of NSCLC
patients harboring activating EGFR mutations.4, 5, 6, 7 The efficacy of EGFR-TKI treatment …

… The latter cohort of patients was part of a clinical trial of erlotinib for patients with
bronchioloalveolar carcinoma. The analysis presented here includes specimens we previously …

… predicts responsiveness to erlotinib and gefitinib.[17,18] The role of erlotinib in EGFR mutated
… In a phase I dose escalation study, a cohort of 22 patients with advanced NSCLC who had …